Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

Helen did say something new. It’s kind of self-evident but I’ve never heard her say it before in all the years she has been at Halozyme. In response to the analyst question regarding the “going assumption that Pegph20 will read out positive, she said Halozyme is “seeking to get more of an already approved drug into the tumor. We are not testing something that’s scientifically interesting and hypothetically going to work; we are trying to drug that is already approved and more of it into the tumor.”

“Our phase 3 can be positive with as little as 2.2 months benefit.” Phase 2 showed 4 months benefit.

As they are scrubbing the data and this close to the public release, she would not have be sounding so enthusiastically if the data was staring to look bad. She would have started to dampen expectations if she had sense that things are looking bad.